|1.||Yasuda, Toshihiro: 20 articles (04/2015 - 05/2004)|
|2.||Takeshita, Haruo: 13 articles (04/2015 - 01/2006)|
|3.||Kawai, Yasuyuki: 13 articles (08/2014 - 05/2004)|
|4.||Fujihara, Junko: 11 articles (04/2015 - 01/2006)|
|5.||Ueki, Misuzu: 10 articles (04/2015 - 07/2005)|
|6.||Kominato, Yoshihiko: 10 articles (01/2014 - 11/2005)|
|7.||Stamatoyannopoulos, John A: 9 articles (06/2015 - 03/2011)|
|8.||Iida, Reiko: 9 articles (04/2015 - 07/2006)|
|9.||Nakajima, Tamiko: 7 articles (01/2014 - 07/2006)|
|10.||Arakawa, Kenichiro: 6 articles (05/2012 - 05/2004)|
02/01/2007 - "The use of DNAse I pre-treatment significantly increases the reliability and sensitivity of immunodetection of CKI nuclear factors, and should be useful for both developmental neurobiology studies as well as cancer diagnostic applications."
10/15/2015 - "Despite independent observations of such phenomena in diverse cancers for over 50 years, the potential for using DNase I as a clinical tool to prevent or treat cancer remains unexplored. "
02/01/2009 - "Incubation with DNase I inhibits tumor cell proliferation."
07/01/2004 - "Interestingly, degenerative 15-bp repeats found in the U3 region are differentially protected in DNase I footprint analysis by the walleye cell line nuclear extract and regressing-tumor nuclear extract. "
05/15/2002 - "Recent experiments indicate that oral VC:VK(3) increases the life-span of tumor-bearing nude mice and significantly reduces the growth rate of solid tumors without any significant toxicity by reactivating DNase I and II and inducing autoschizis. "
12/29/2000 - "By DNase I hypersensitivity mapping and deletion studies we have identified a 269-base pair activator element located 4.9 kilobases upstream from the transcription start site that acts as an enhancer. "
08/25/2000 - "To locate liver-specific elements in other segments of the human gene, DNase I hypersensitivity studies were performed with transcriptionally active, liver-derived HepG2 cells and with transcriptionally inactive HeLa cells. "
10/17/1996 - "DNase I hypersensitivity studies showed increased DNase I resistance and the loss of a hypersensitive site in differentiated F9 cells. "
05/13/1994 - "In order to localize the critical regulatory elements important for tissue-specific, high level WAP gene expression, DNase I hypersensitivity mapping studies of WAP transgenes were performed in nuclei isolated from mammary gland and liver. "
08/01/1993 - "We have chosen to use the approaches involving in situ nick translation and have shown that the patterns of DNase I hypersensitivity and of CpG islands on human chromosomes show a strict correspondence to R-banding patterns: Deviations from R-banding patterns reported by previous investigators who have made similar studies appear to be attributable to excessive digestion.(ABSTRACT TRUNCATED AT 250 WORDS)"
|3.||Cystic Fibrosis (Mucoviscidosis)
04/01/2001 - "Improved activity of an actin-resistant DNase I variant on the cystic fibrosis airway secretions."
11/01/2012 - "Moreover, as shown above, DNase I is utilized in the treatment of patients with cystic fibrosis. "
02/01/2004 - "The current status of deoxyribonuclease I in the management of cystic fibrosis was investigated and special attention given to the developments in delivery systems, such as dry powder inhalation. "
08/06/1996 - "Engineering actin-resistant human DNase I for treatment of cystic fibrosis."
07/17/1998 - "Improved potency of hyperactive and actin-resistant human DNase I variants for treatment of cystic fibrosis and systemic lupus erythematosus."
|4.||Pressure Ulcer (Bedsore)
01/01/1985 - "In a single-blind, randomized trial, the efficacy of topical streptokinase-streptodornase (Varidase) solution was compared with that of zinc oxide on necrotic pressure ulcers in 28 patients. "
07/01/1996 - "In a randomised, double-blind, controlled trial, a comparison was made of the relative efficacy of using streptokinase/streptodornase (Varidase) in a hydrogel (KY Jelly) or the hydrogel alone in the debridement of Grade IV pressure sores. "
|5.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
08/01/2014 - "In the present study, we have extensively continued our previous investigations of the nonsynonymous single-nucleotide polymorphisms (SNPs) in the human DNase I (DNASE1) gene potentially relevant to systemic lupus erythematosus (SLE); therefore, all of the 58 nonsynonymous SNPs registered in the NCBI dbSNP database could be evaluated and it could be checked as to whether these SNPs might serve as a functional SNP. "
04/01/2007 - "Study of DNASE I gene polymorphisms in systemic lupus erythematosus susceptibility."
06/10/1973 - "[Studies on DNase I activity and its heat-labile inhibitor in systemic lupus erythematosus]."
02/10/1970 - "[Studies on Dnase I activity in systemic lupus erythematosus]."
08/01/2014 - "Identification of the functional alleles of the nonsynonymous single-nucleotide polymorphisms potentially implicated in systemic lupus erythematosus in the human deoxyribonuclease I gene."
|2.||DNA (Deoxyribonucleic Acid)
|3.||Streptodornase and Streptokinase
|4.||Pancreatic Ribonuclease (Ribonuclease A)
|9.||Immunoglobulin G (IgG)
|10.||DNA-Directed RNA Polymerases (RNA Polymerase)
|5.||Nutritional Support (Artificial Feeding)